Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Formation of platinum (II) as a six member ring for sustained polymeric delivery.

Senadheera SN, Zhang T, Groer CE, Forrest ML.

Eur J Med Chem. 2017 Aug 18;136:452-456. doi: 10.1016/j.ejmech.2017.05.020. Epub 2017 May 6.

2.

Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.

Crowley RS, Riley AP, Sherwood AM, Groer CE, Shivaperumal N, Biscaia M, Paton K, Schneider S, Provasi D, Kivell BM, Filizola M, Prisinzano TE.

J Med Chem. 2016 Dec 22;59(24):11027-11038. doi: 10.1021/acs.jmedchem.6b01235. Epub 2016 Dec 13.

3.

Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.

Riley AP, Groer CE, Young D, Ewald AW, Kivell BM, Prisinzano TE.

J Med Chem. 2014 Dec 26;57(24):10464-75. doi: 10.1021/jm501521d. Epub 2014 Dec 9.

4.

Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A.

Vasiljevik T, Groer CE, Lehner K, Navarro H, Prisinzano TE.

J Nat Prod. 2014 Aug 22;77(8):1817-24. doi: 10.1021/np5002048. Epub 2014 Jul 30.

5.

Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.

Schmid CL, Streicher JM, Groer CE, Munro TA, Zhou L, Bohn LM.

J Biol Chem. 2013 Aug 2;288(31):22387-98. doi: 10.1074/jbc.M113.476234. Epub 2013 Jun 17.

6.

Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.

Béguin C, Potuzak J, Xu W, Liu-Chen LY, Streicher JM, Groer CE, Bohn LM, Carlezon WA Jr, Cohen BM.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1023-6. doi: 10.1016/j.bmcl.2011.11.128. Epub 2011 Dec 7.

7.

Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Raehal KM, Schmid CL, Groer CE, Bohn LM.

Pharmacol Rev. 2011 Dec;63(4):1001-19. doi: 10.1124/pr.111.004598. Epub 2011 Aug 26. Review.

8.

Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation.

Groer CE, Schmid CL, Jaeger AM, Bohn LM.

J Biol Chem. 2011 Sep 9;286(36):31731-41. doi: 10.1074/jbc.M111.248310. Epub 2011 Jul 14.

9.

Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain.

Tarselli MA, Raehal KM, Brasher AK, Streicher JM, Groer CE, Cameron MD, Bohn LM, Micalizio GC.

Nat Chem. 2011 Jun;3(6):449-53. doi: 10.1038/nchem.1050.

PMID:
21602859
10.

Herkinorin analogues with differential beta-arrestin-2 interactions.

Tidgewell K, Groer CE, Harding WW, Lozama A, Schmidt M, Marquam A, Hiemstra J, Partilla JS, Dersch CM, Rothman RB, Bohn LM, Prisinzano TE.

J Med Chem. 2008 Apr 24;51(8):2421-31. doi: 10.1021/jm701162g. Epub 2008 Apr 2.

11.

An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.

Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, Bohn LM.

Mol Pharmacol. 2007 Feb;71(2):549-57. Epub 2006 Nov 7.

Supplemental Content

Loading ...
Support Center